Japanese Start-Up Gets Fast-Track Status For Flu Vaccine
This article was originally published in PharmAsia News
Japan's Health Ministry has granted fast-track status to a startup drug maker's application to begin human trials on a flu vaccine. The UMN-0501 vaccine was developed by UMN Pharma, which mass produced it in cultures of cells rather than using chicken eggs. The new process allows for an eight-week turnaround. UMN could be ready to submit its drug as early as 2010 under the ministry's orphan drug system. (Click here for more - a subscription may be required
You may also be interested in...
Guardant’s CEO anticipates accelerated adoption and reimbursement of its FDA-approved liquid biopsy assay and more biopharma partnerships.
Public Company Edition: The German mRNA-focused company could raise up to $245m based on its proposed price range, but investor interest could drive the offering’s total higher. Also, Perceptive launches another SPAC, Regeneron sells $2bn in debt and Biohaven secures up to $950m.
Agency commissioner appeals to AMA audience to communicate message that FDA review decisions are based on good science.